December 2025 in “Journal of Human Immunity” JAK inhibitors may help improve symptoms in adults with APECED.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
November 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may reduce depression in people with alopecia areata.
August 2025 in “International Journal of Women’s Dermatology” Stopping and restarting JAK inhibitors during pregnancy in women with alopecia areata leads to hair loss and regrowth, with most pregnancies resulting in healthy babies.
June 2025 in “Medical alphabet” JAK inhibitors may help treat alopecia areata in children, but their safety needs careful evaluation.
June 2025 in “Patient Preference and Adherence” Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.
March 2018 in “Suez Canal University Medical Journal” New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
April 2017 in “Journal of Investigative Dermatology” Blocking JAK-STAT5 signaling in mice leads to hair growth.
May 2026 in “International Journal of Molecular Sciences” Chemotherapy-induced hair loss may be linked to immune system changes, and certain treatments could help but need careful use.
March 2026 in “Mendeley Data” Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.
A few users dominate Reddit discussions on JAK inhibitors, highlighting social media's potential for tracking drug safety but needing expert oversight.
February 2026 in “Journal of Drugs in Dermatology” Janus kinase inhibitors are effective and safe for treating alopecia areata.
September 2025 in “Chinese Journal of Chromatography” A new method accurately detects illegal JAK inhibitors in hair loss cosmetics.
July 2025 in “Journal of Investigative Dermatology” Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.
June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
August 2024 in “New Zealand Medical Student Journal” JAK inhibitors show promise for treating skin diseases effectively and safely.
February 2024 in “Australasian journal of dermatology” Janus kinase inhibitors may help treat lichen planopilaris.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
17 citations
,
May 2019 in “BMJ Open” JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.
4 citations
,
April 2019 in “Cell Stem Cell” Certain immune cells in the skin can stop hair from growing.